Additional baricitinib loading dose improves clinical outcome in COVID-19
Pneumonia associated with coronavirus disease 2019 (COVID-19) has been accounted for high mortality rate in severe COVID-19 worldwide, and additional serious scarcity of standard and effective anti-inflammatory drug in COVID-19 pneumonia management is a big challenge. Baricitinib, a Janus kinase (JA...
Guardado en:
Autores principales: | Hasan Md Jahidul, Rabbani Raihan, Anam Ahmad Mursel, Huq Shihan Mahmud Redwanul |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
De Gruyter
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fa98f059064f41fa9868c28725b9263a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Baricitinib for the treatment of rheumatoid arthritis
por: Ivan Urits, et al.
Publicado: (2020) -
Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
por: Giulia Radi, et al.
Publicado: (2021) -
Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19
por: Mar Masiá, et al.
Publicado: (2021) -
Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Miguel Nogueira, et al.
Publicado: (2021) -
To the question of biosafe level of exposure of relatively-pathogenic yeast-like mycotic substances
por: L. M. Sosedova
Publicado: (2013)